The taxanes and Herceptin® have been shown to possess significant clinical activity in metastatic breast cancer. Preclinical testing of taxane/Herceptin combinations demonstrated additive and synergistic interactions with paclitaxel and docetaxel, respectively. In a pivotal clinical trial, combination of paclitaxel (3-weekly) and Herceptin was associated with an increased response rate compared with paclitaxel monotherapy (41% vs. 17%; p = 0.001). The combination therapy also significantly improved time to disease progression (6.9 vs. 2.7 months; p < 0.05). In a phase II study of weekly paclitaxel plus Herceptin in patients with normal or increased tumor HER2 levels, a response was observed in 60% of patients and the regimen was well tolerated. Responses were more frequent in patients with HER2-overexpressing tumors (83% vs. 45%). Preliminary results from a phase II study of Herceptin plus docetaxel in patients with HER2-overexpressing tumors indicate significant activity, with a response observed in 7 (44%) of 16 evaluable patients. The preliminary results of a trial of weekly docetaxel and Herceptin demonstrate a response rate of 54% in 13 evaluable patients. Additional European trials of Hercep- tin/taxane combinations as first- and second-line and adjuvant therapy are ongoing. The results of the studies to date indicate that regimens combining Herceptin with 3-weekly and weekly taxane are effective and well tolerated.

1.
Abrams JS, Vena DA, Baltz J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center Trial. J Clin Oncol 1995;13:2056–2065.
2.
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (HerceptinTM) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825–2831.
3.
Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 1997;11(suppl 2):43–48.
4.
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737–744.
5.
Brenner TL, Adams VR: First MAb approved for the treatment of metastatic breast cancer. J Am Pharm Assoc 1999;39:236–238.
6.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.
7.
Davidson NG: Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 1996;23(suppl 11):6–10.
8.
Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996;7:165–171.
9.
Guastalla JP, Bonnetterre J, Fumoleau P, Piccart M, Tubiana M, Chevallier B, Nieamann C, Alakl M, Nichol A, Riva A, Marty M: A phase II trial of docetaxel in patients with anthracycline-resistant metastatic breast cancer. Eur J Cancer 1995;31(suppl 5):S75–S77.
10.
Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575–4580.
11.
Harris JR, Morrow M, Norton L: Malignant tumors of the breast; in DeVita VT, Hellman S and Rosenberg SA (eds): Cancer, Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 1557–1616.
12.
Hortobagyi GN: Recent progress in the clinical development of docetaxel. Semin Oncol 1999;26(suppl 9):32–36.
13.
Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58–65.
14.
Kuzur ME, Albain KS, Huntington MO, Jones SF, Hainsworth JD, Greco FA, Erland JB, Vogel CL, Burris HA: A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Am Soc Clin Oncol 2000;19:131A.
15.
Leyland-Jones B, Arnold A, Gelmon K, Verma S, Rakhit A, Howell J. A pharmacokinetic (PK) study of Herceptin® administered with paclitaxel i.v. every 3 weeks. Eur J Cancer 2000a; S35:abstract 41.
16.
Leyland-Jones B, Hemmings F, Arnold A, Gelmon K, Verma S, Ayoub J-P. Pharmacokinetics of Herceptin® administered with paclitaxel every three weeks. Cancer Res Treat 2000b;124:abstract 534.
17.
Leyland-Jones B, Smith I: Role of Herceptin® in primary breast cancer: Views from North America and Europe. Oncology 2001;61(suppl 2):83–91.
18.
Nicholson BP, Thor AD, Goldstein LJ, Merkel DE, Gradishar WJ, Sledge GW: Weekly docetaxel (D) and Rhumabher2 (H) combination therapy as first- or second-line treatment for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000;19:139A.
19.
Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, Mendelsohn J, Bajamonde A, Ash M, Shak S: Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus humanized anti-HER2 monoclonal antibody herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999;18:127A.
20.
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241–2251.
21.
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–2671.
22.
Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829–1838.
23.
Ravdin PM: Treatment of patients resistant to anthracycline therapy. Anticancer Drugs 1996;7(suppl 2):13–16.
24.
Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879–2885.
25.
Rowinsky EK: Paclitaxel pharmacology and other tumor types. Semin Oncol 1997;24(suppl 19):1–12.
26.
Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:1183–1232.
27.
Seidman AD, Fornier M, Esteva F, Tan L, Kaptain S, Bach A, Arroyo CD, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, D’Andrea G, Sklarin N, Dickler M, Chin J, Denton C, Bacotti D, Willey J, Frye D, Hortobagyi G, Norton L, Hudis C: Final report: weekly (W) Herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): analysis of efficacy by HER2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescence in-situ hybridization (FISH)]. Proc Am Soc Clin Oncol 2000;19:83A.
28.
Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995a;13:2575–2581.
29.
Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995b;13:11152–11159.
30.
Seidman AD: One hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index. Oncology 1998;12(suppl 1):19–22.
31.
Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
32.
ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:527–532.
33.
Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM: Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996;14:422–428.
34.
Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886–2894.
35.
Yeung K, Gupta R, Haidak D, Katzen H, Greer J, Quader ML: Weekly (W) Herceptin (H, trastuzimab) and one hour Taxol (T, paclitaxel) infusion (WHT) regimen for human epidermal growth factor receptor-2 (HER2) overexpressed (+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000;19:142A.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.